Grufity logoGrufity logo
StocksFundsSearch Filings

Innoviva Inc Stock Research

INVA

13.17USD+0.06(+0.46%)Market Closed

Market Summary

USD13.17+0.06
Market Closed
0.46%

INVA Alerts

INVA Stock Price

INVA RSI Chart

INVA Valuation

Market Cap

866.9M

Price/Earnings (Trailing)

3.94

Price/Sales (Trailing)

3.19

EV/EBITDA

2.4

Price/Free Cashflow

6.71

INVA Price/Sales (Trailing)

INVA Profitability

EBT Margin

100.60%

Return on Equity

38.93%

Return on Assets

17.89%

Free Cashflow Yield

14.91%

INVA Fundamentals

INVA Revenue

Revenue (TTM)

271.5M

Revenue Y/Y

-15.2%

Revenue Q/Q

287.68%

INVA Earnings

Earnings (TTM)

220.3M

Earnings Y/Y

-249.65%

Earnings Q/Q

-129.79%

Price Action

52 Week Range

10.6415.67
(Low)(High)

Last 7 days

0.2%

Last 30 days

14.2%

Last 90 days

19.8%

Trailing 12 Months

-13.2%

INVA Financial Health

Current Ratio

3.29

INVA Investor Care

Buy Backs (1Y)

5.42%

Diluted EPS (TTM)

2.57

Peers (Alternatives to Innoviva)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
409.0B
96.3B
-3.62% -9.57%
32.14
4.25
1.46% -35.83%
398.5B
27.7B
2.58% 47.15%
70.08
14.39
-5.56% -7.22%
272.8B
57.9B
-4.82% 28.79%
17.88
4.63
7.21% -8.11%
230.9B
93.0B
-0.23% -25.99%
7.36
2.3
0.56% 16.36%
150.1B
45.8B
-1.47% -11.26%
23.72
3.25
-2.37% 16.96%
MID-CAP
5.0B
4.6B
-12.00% -16.92%
-35.25
1.11
8.46% -29.07%
3.5B
1.5M
-8.84% 225.36%
-11.32
1.6K
-86.94% -16.59%
SMALL-CAP
1.8B
668.5M
-9.91% 19.28%
34.95
2.72
11.17% -29.04%
1.6B
596.3M
-7.75% -62.41%
-0.89
2.66
-3.41% -3791.67%
866.9M
271.5M
14.22% -13.24%
3.94
3.19
-31.50% -40.28%
666.4M
112.3M
-6.91% -41.08%
-4.29
5.94
7.69% 41.96%
590.7M
30.8M
-2.33% -39.30%
-6.14
19.16
378.90% -19.01%
536.4M
51.7M
11.79% 117.61%
-6.04
10.38
4.69% -299.77%
401.1M
478.9M
-31.81% -82.48%
-0.13
0.84
-31.50% -634.70%
94.1M
2.2B
-43.99% -88.43%
-0.03
0.04
-25.47% -292.77%

Financials for Innoviva

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-4.8%272285373404396
Operating Expenses-144.6%-59.81134113--
  S&GA Expenses20.8%77.0064.0049.0024.0017.00
  R&D Expenses16.3%48.0041.0031.0020.006.00
EBITDA-27.7%319441275392-
EBITDA Margin-5.4%1.12*1.18*0.68*0.99*-
Earnings Before Taxes-1.2%283287408245361
EBT Margin-8.0%1.01*1.09*0.61*0.91*-
Interest Expenses9.0%17.0016.0017.0016.0017.00
Net Income-34.1%220334208297-
Net Income Margin-13.8%0.77*0.90*0.51*0.75*-
Free Cahsflow-30.7%202291372378-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-8.3%1,1301,2311,3281,1381,107
  Current Assets-33.2%296444455400318
    Cash Equivalents-50.5%144291301284217
  Inventory-11.2%50.0056.0071.00--
  Net PPE5.9%0.000.000.000.000.00
  Goodwill4.6%28.0027.0016.006.006.00
  Current Liabilities-71.7%38.00135164126109
    LT Debt, Non Current0.1%445444444443443
Shareholder's Equity-0.8%561566641565552
  Retained Earnings17.0%-170-204-136-402-403
  Additional Paid-In Capital-3.4%1,1251,1641,1711,1841,183
Shares Outstanding-4.9%66.0069.0070.0070.0070.00
Minority InterestNaN%--177166-
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-35.9%129202291372378
  Share Based Compensation8.8%8.007.007.003.003.00
Cashflow From Investing189.7%51.00-56.63-67.86-165-73.04
Cashflow From Financing-355.0%-252-55.57-57.6334.00-370
  Buy Backs479.1%49.009.000.000.000.00

Risks for INVA

What is the probability of a big loss on INVA?

73.1%


Probability that Innoviva stock will be more than 20% underwater in next one year

61.9%


Probability that Innoviva stock will be more than 30% underwater in next one year.

39.6%


Probability that Innoviva stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Innoviva was unfortunately bought at previous high price.

Drawdowns

Returns for INVA

Cumulative Returns on INVA

2.3%


7-Year Cumulative Returns

-2.5%


5-Year Cumulative Returns

-1.7%


3-Year Cumulative Returns

What are the long-term rolling returns for INVA?

FIve years rolling returns for Innoviva.

Annualized Returns

Which funds bought or sold INVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-06-01
MACQUARIE GROUP LTD
reduced
-90.89
-765,000
64,000
-%
2023-05-26
ProShare Advisors LLC
reduced
-11.81
-52,413
156,195
-%
2023-05-25
Brandywine Global Investment Management, LLC
sold off
-100
-2,423,460
-
-%
2023-05-23
ROYCE & ASSOCIATES LP
added
18.17
4,375
1,320,980
0.01%
2023-05-22
EMC Capital Management
unchanged
-
-57,000
322,000
0.27%
2023-05-22
PUTNAM INVESTMENTS LLC
unchanged
-
-376,856
5,394,980
0.01%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-0.12
-501,375
2,795,620
-%
2023-05-22
PUTNAM INVESTMENTS LLC
added
20.14
1,330,760
67,592,000
0.11%
2023-05-18
JPMORGAN CHASE & CO
reduced
-10.62
-1,073,000
3,374,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-6.73
-602,000
2,289,000
-%

1–10 of 45

Latest Funds Activity

Are funds buying INVA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own INVA
No. of Funds

Innoviva News

Defense World
HighTower Advisors LLC Purchases Shares of 36692 Innoviva, Inc ....
Defense World,
17 hours ago
Investing.com India
InvestorsObserver
StockNews.com

Schedule 13G FIlings of Innoviva

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 15, 2023
sarissa capital management lp
10.54%
6,904,000
SC 13D/A
Feb 14, 2023
putnam investments llc
7.6%
5,329,107
SC 13G
Feb 13, 2023
renaissance technologies llc
6.06%
4,229,607
SC 13G/A
Feb 10, 2023
blackrock inc.
15.2%
10,611,839
SC 13G/A
Feb 09, 2023
vanguard group inc
10.13%
7,072,212
SC 13G/A
Feb 02, 2023
westfield capital management co lp
5.88%
4,106,136
SC 13G/A
Jan 26, 2023
blackrock inc.
10.6%
5,671,100
SC 13G/A
Jan 20, 2023
blackrock inc.
10.6%
5,671,100
SC 13G
Jul 11, 2022
vanguard group inc
10.00%
6,970,950
SC 13G/A
Feb 11, 2022
renaissance technologies llc
7.62%
5,295,133
SC 13G/A

INVA Fair Value

Show Fair-Value

Recent SEC filings of Innoviva

View All Filings
Date Filed Form Type Document
May 30, 2023
4
Insider Trading
May 24, 2023
4
Insider Trading
May 24, 2023
4
Insider Trading
May 24, 2023
4
Insider Trading
May 24, 2023
4
Insider Trading
May 24, 2023
4
Insider Trading
May 24, 2023
4
Insider Trading
May 24, 2023
8-K
Current Report
May 24, 2023
8-K
Current Report
May 23, 2023
4
Insider Trading

Latest Insider Trading transactions for INVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-30
DENNER ALEXANDER J
bought
1,560,650
13.0054
120,000
-
2023-05-26
DENNER ALEXANDER J
bought
393,729
13.1243
30,000
-
2023-05-25
DENNER ALEXANDER J
bought
654,330
13.0866
50,000
-
2023-05-22
Srivastava Sapna
acquired
-
-
16,495
-
2023-05-22
DiPaolo Mark
acquired
-
-
16,495
-
2023-05-22
Schlesinger Sarah J.
acquired
-
-
16,495
-
2023-05-22
Birx Deborah
acquired
-
-
16,495
-
2023-05-22
Odysseas Kostas D
acquired
-
-
16,495
-
2023-05-22
Haimovitz Jules
acquired
-
-
16,495
-
2023-05-19
Zhen Marianne
sold (taxes)
-10,560
13.47
-784
chief accounting officer

1–10 of 50

Pavel Raifeld
5
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:  
Total revenue$ 76,372$ 90,059
Expenses:  
Selling, general and administrative19,7356,492
Research and development12,5885,838
Amortization of acquired intangible assets3,8050
Loss on extinguishment of debt020,662
Changes in fair values of equity method investments, net(15,817)11,950
Changes in fair values of other equity and long-term investments, net2,164(2,539)
Interest and dividend income(3,365)(322)
Interest expense4,4273,010
Other expense, net1,346250
Total expenses35,23245,341
Income before income taxes41,14044,718
Income tax expense, net6,2756,860
Net income34,86537,858
Net income attributable to noncontrolling interests022,085
Net income attributable to Innoviva stockholders$ 34,865$ 15,773
Basic net income per share attributable to Innoviva stockholders$ 0.51$ 0.23
Diluted net income per share attributable to Innoviva stockholders$ 0.42$ 0.20
Shares used to compute Innoviva basic and diluted net income per share:  
Shares used to compute basic net income per share67,78669,544
Shares used to compute diluted net income per share89,78893,730
Royalty revenue  
Revenue:  
Total revenue$ 56,858$ 90,059
Net product sales  
Revenue:  
Total revenue11,5140
Expenses:  
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)8,7490
License revenue  
Revenue:  
Total revenue8,0000
License  
Expenses:  
Cost of license revenue$ 1,600$ 0

INVA Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 144,049$ 291,049
Accounts receivable , net15,4909,401
Receivables from collaboration arrangement60,31454,672
Inventory49,65355,897
Prepaid expenses24,11929,559
Other current assets2,8212,933
Total current assets296,446443,511
Property and equipment, net180170
Equity Method Investment54,97139,154
Equity and long-term investments400,894363,859
Capitalized fees paid, net94,15197,607
Right-of-use assets2,9733,265
Goodwill27,94626,713
Intangible assets248,314252,919
Other assets3,8934,299
Total assets1,129,7681,231,497
Current liabilities:  
Accounts payable5,9332,939
Accrued personnel-related expenses4,2238,022
Accrued interest payable8334,359
Deferred revenue2,0942,094
Convertible subordinated notes due 2023, net of issuance costs096,193
Income tax payable154154
Other accrued liabilities24,90021,207
Total current liabilities38,137134,968
Long-term debt, net of discount and issuance costs444,692444,180
Other long-term liabilities70,13370,918
Deferred tax liabilities, net5,3925,771
Income tax payable, long-term9,9219,872
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding00
Common stock: $0.01 par value, 200,000 shares authorized, 65,824 and 69,188 issued and outstanding as of March 31, 2023 and December 31, 2022, respectively659692
Treasury stock: at cost, 32,005 shares as of March 31, 2023 and December 31, 2022, respectively(393,829)(393,829)
Additional paid-in capital1,124,7091,163,836
Accumulated deficit(170,046)(204,911)
Total stockholders' equity561,493565,788
Total liabilities and stockholders' equity$ 1,129,768$ 1,231,497